TNFRSF17 and Miyoshi myopathy: BCMA has consequently emerged as a promising diagnostic and prognostic marker of disease and a therapeutic target of interest in hematological malignancies—particularly in MM and its precursor neoplasms [10] (Phase I trial #: NCT05055063).